DK3013964T3 - Sammensætninger til indføring af rna i celler - Google Patents
Sammensætninger til indføring af rna i celler Download PDFInfo
- Publication number
- DK3013964T3 DK3013964T3 DK14742474.1T DK14742474T DK3013964T3 DK 3013964 T3 DK3013964 T3 DK 3013964T3 DK 14742474 T DK14742474 T DK 14742474T DK 3013964 T3 DK3013964 T3 DK 3013964T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- cells
- introducing rna
- rna
- introducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
- C08G73/0213—Preparatory process
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13174390 | 2013-06-28 | ||
EP13181380 | 2013-08-22 | ||
PCT/EP2014/063756 WO2014207231A1 (en) | 2013-06-28 | 2014-06-27 | Compositions for introducing rna into cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3013964T3 true DK3013964T3 (da) | 2020-06-15 |
Family
ID=51224914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14742474.1T DK3013964T3 (da) | 2013-06-28 | 2014-06-27 | Sammensætninger til indføring af rna i celler |
Country Status (13)
Country | Link |
---|---|
US (1) | US12064484B2 (da) |
EP (1) | EP3013964B1 (da) |
JP (1) | JP6609246B2 (da) |
KR (1) | KR102285326B1 (da) |
CN (1) | CN105579584B (da) |
AU (1) | AU2014300980B2 (da) |
BR (1) | BR112015032225B1 (da) |
CA (1) | CA2916800C (da) |
DK (1) | DK3013964T3 (da) |
EA (1) | EA036400B1 (da) |
ES (1) | ES2810298T3 (da) |
WO (1) | WO2014207231A1 (da) |
ZA (1) | ZA201509111B (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2663360T3 (es) | 2011-06-08 | 2018-04-12 | Translate Bio, Inc. | Lípidos escindibles |
WO2015128030A1 (en) * | 2014-02-26 | 2015-09-03 | Ethris Gmbh | Compositions for gastrointestinal administration of rna |
MX2016014881A (es) | 2014-05-14 | 2017-05-01 | Alex Levitzki Man And Holdings Ltd | Vectores mejorados de polietilenimina polietilenglicol. |
CN113786498A (zh) * | 2014-11-10 | 2021-12-14 | 埃泽瑞斯公司 | 通过递送bmp编码rna诱导骨生成 |
BR122023027721A2 (pt) | 2015-06-30 | 2024-01-30 | ethris GmbH | Composição |
CO2018006699A2 (es) * | 2015-12-01 | 2018-09-20 | Spark Therapeutics Inc | Métodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspensión sin suero adecuado para uso clínico |
RU2751001C2 (ru) * | 2016-06-09 | 2021-07-07 | Кьюрвак Аг | Гибридные носители для доставки нуклеиновых кислот |
CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
WO2018127382A1 (en) | 2017-01-03 | 2018-07-12 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
WO2019204451A1 (en) * | 2018-04-17 | 2019-10-24 | Carnegie Mellon University | Enhanced lipid nanoparticle drug delivery using a negatively charged polymer |
CA3098259C (en) * | 2018-04-25 | 2024-02-20 | Ethris Gmbh | Lipid-based formulations for the delivery of rna |
EP3923971B1 (en) | 2019-02-14 | 2023-12-20 | ethris GmbH | Analyzing the effect of a polyribonucleotide on ciliogenesis |
CN111249476B (zh) * | 2020-02-19 | 2023-09-26 | 深圳厚存纳米药业有限公司 | 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒 |
AU2021375281A1 (en) | 2020-11-04 | 2023-06-01 | Ethris Gmbh | Use of ifn-lambda mrna for treating viral infections |
EP4297722A1 (en) | 2021-02-26 | 2024-01-03 | Ethris GmbH | Formulations for aerosol formation and aerosols for the delivery of nucleic acid |
EP4333810A1 (en) * | 2021-05-07 | 2024-03-13 | Carnegie Mellon University | Lipid nanoparticle-mediated mrna delivery to the pancreas |
CN113876639B (zh) * | 2021-11-12 | 2023-08-22 | 湖北省麦诗特生物科技有限公司 | 一种含有提高皮肤弹性脂质体的面霜组合物及其制备方法 |
WO2024042236A1 (en) | 2022-08-26 | 2024-02-29 | Ethris Gmbh | Stable lipid or lipidoid nanoparticle suspensions |
EP4327829A1 (en) | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
WO2024121160A1 (en) | 2022-12-05 | 2024-06-13 | Ethris Gmbh | Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency |
WO2024184626A2 (en) | 2023-03-03 | 2024-09-12 | Diosynvax Ltd | Coronavirus vaccines |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
JP4538150B2 (ja) * | 1998-08-14 | 2010-09-08 | ヴァレンティス,インコーポレイテッド | 核酸分子の保護された単一バイアル調製物、インライン混合によってそれを形成する方法、及び関連する生成物及び方法 |
ATE383331T1 (de) | 1998-11-12 | 2008-01-15 | Invitrogen Corp | Transportreagentien |
DE50006269D1 (de) | 1999-06-25 | 2004-06-03 | Stemberger Axel | Kombinationen zur einführung von nucleinsäuren in zellen |
EP1297169B1 (en) | 2000-06-26 | 2012-08-08 | Ethris Gmbh | Method for transfecting cells using a magnetic field |
CA2445523A1 (en) | 2001-04-30 | 2002-11-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composite scaffolds and methods using same for generating complex tissue grafts |
JP4535229B2 (ja) | 2003-05-08 | 2010-09-01 | 国立大学法人 東京大学 | ポリエチレングリコール−ポリカチオンブロック共重合体 |
CN101124316A (zh) * | 2004-12-17 | 2008-02-13 | 日东电工株式会社 | 用于转染真核细胞的固定的可降解阳离子聚合物 |
WO2006085664A1 (ja) | 2005-02-10 | 2006-08-17 | The University Of Tokyo | ポリカチオン荷電性ポリマー及び核酸のキャリヤーとしての使用 |
US20060235459A1 (en) | 2005-04-19 | 2006-10-19 | Das Gladwin S | Balloon catheters and methods for manufacture |
EP2476756A1 (en) | 2005-06-15 | 2012-07-18 | Massachusetts Institute of Technology | Amine-containing lipids and uses thereof |
SI3611266T1 (sl) | 2005-08-23 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo |
US20120021042A1 (en) * | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
EP1973927B1 (en) | 2005-12-15 | 2013-08-14 | Centre National de la Recherche Scientifique - CNRS | Cationic oligonucleotides, automated methods for preparing same and their uses |
CA2742954C (en) * | 2008-11-07 | 2018-07-10 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
WO2010065660A2 (en) * | 2008-12-02 | 2010-06-10 | University Of Utah Research Foundation | Biodegradable polydisulfide amines for gene delivery |
EP2459231B1 (de) | 2009-07-31 | 2016-06-08 | Ethris Gmbh | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
US9168230B2 (en) * | 2011-05-26 | 2015-10-27 | University Of South Carolina | Tetrary gene delivery system for gene therapy and methods of its use |
DE102011114986A1 (de) | 2011-09-28 | 2013-03-28 | Ethris Gmbh | Sprühsystem |
MX354267B (es) | 2011-10-03 | 2018-02-21 | Moderna Therapeutics Inc Star | Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos. |
WO2014066811A1 (en) * | 2012-10-25 | 2014-05-01 | The Johns Hopkins University | Bioreducible poly (b-amino ester)s for sirna delivery |
RU2649364C2 (ru) * | 2011-12-16 | 2018-04-02 | Модерна Терапьютикс, Инк. | Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты |
EP2882706A1 (en) * | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Amine-containing lipidoids and uses thereof |
-
2014
- 2014-06-27 DK DK14742474.1T patent/DK3013964T3/da active
- 2014-06-27 WO PCT/EP2014/063756 patent/WO2014207231A1/en active Application Filing
- 2014-06-27 BR BR112015032225-5A patent/BR112015032225B1/pt active IP Right Grant
- 2014-06-27 CA CA2916800A patent/CA2916800C/en active Active
- 2014-06-27 US US14/901,467 patent/US12064484B2/en active Active
- 2014-06-27 KR KR1020167001398A patent/KR102285326B1/ko active IP Right Grant
- 2014-06-27 EA EA201600044A patent/EA036400B1/ru not_active IP Right Cessation
- 2014-06-27 CN CN201480048096.7A patent/CN105579584B/zh active Active
- 2014-06-27 ES ES14742474T patent/ES2810298T3/es active Active
- 2014-06-27 AU AU2014300980A patent/AU2014300980B2/en active Active
- 2014-06-27 JP JP2016522546A patent/JP6609246B2/ja active Active
- 2014-06-27 EP EP14742474.1A patent/EP3013964B1/en active Active
-
2015
- 2015-12-14 ZA ZA2015/09111A patent/ZA201509111B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US12064484B2 (en) | 2024-08-20 |
BR112015032225B1 (pt) | 2022-05-17 |
ES2810298T3 (es) | 2021-03-08 |
KR102285326B1 (ko) | 2021-08-04 |
CN105579584B (zh) | 2020-08-28 |
EP3013964A1 (en) | 2016-05-04 |
JP2016524898A (ja) | 2016-08-22 |
BR112015032225A2 (pt) | 2017-07-25 |
CA2916800C (en) | 2022-10-25 |
JP6609246B2 (ja) | 2019-11-20 |
EA201600044A1 (ru) | 2016-06-30 |
AU2014300980B2 (en) | 2020-03-05 |
CA2916800A1 (en) | 2014-12-31 |
WO2014207231A1 (en) | 2014-12-31 |
ZA201509111B (en) | 2021-03-31 |
AU2014300980A1 (en) | 2016-01-07 |
US20170021036A1 (en) | 2017-01-26 |
EP3013964B1 (en) | 2020-05-06 |
CN105579584A (zh) | 2016-05-11 |
KR20160040524A (ko) | 2016-04-14 |
EA036400B1 (ru) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3013964T3 (da) | Sammensætninger til indføring af rna i celler | |
DK2978419T3 (da) | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf | |
BR112015027279A8 (pt) | métodos e composições para acentuar células t reguladoras cd4+ | |
DK2953634T3 (da) | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler | |
DK3042411T3 (da) | Metalunderstøttet fastoxidbrændselscelle | |
IL290717A (en) | Cell preparations derived from dedifferentiated and reprogrammed cells | |
DK3079658T3 (da) | Kammer til indkapsling af secernerende celler | |
FI11677U1 (fi) | Uusiutuva hiilivetykoostumus | |
DK2686434T3 (da) | Fremgangsmåde til reduktion af viskositet i saccharificeringsproces | |
DK3725778T3 (da) | Formuleringer af enzalutamid | |
DK2941483T3 (da) | Fremgangsmåde til at opnå immunstimulerende dendritriske celler | |
DK3394248T3 (da) | Dendritisk cellesammensætning | |
FI11676U1 (fi) | Uusiutuva hiilivetykoostumus | |
DK3421470T3 (da) | Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form | |
DK2941484T3 (da) | Fremgangsmåde til at opnå immunsuppressive dendritriske celler | |
DK2970843T3 (da) | Fremgangsmåder til frembringelse af cellebank med høj densitet | |
DK3242903T3 (da) | Sammensætninger til at indføre nukleinsyre i celler | |
BR112015001562A2 (pt) | biotinas e composições | |
DE112012001867A5 (de) | Solarkonzentrator | |
DE112012003544A5 (de) | Solarkonzentrator | |
DK3003285T3 (en) | Fast farmaceutisk dosisform til frigivelse af mindst to aktive farmaceutiske ingredienser i mundhulen | |
CL2014002030A1 (es) | Alfa-amilasa | |
BR112016009753A2 (pt) | método de cultura de células. | |
DK2825633T3 (da) | Fremgangsmåde til dyrkning af E. coli-celler til høj densitet | |
DK3046628T3 (da) | Fremgangsmåder og sammensætninger til fremstilling af hepatocyt-lignende celler |